Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: SLAS Discov. 2019 Jul 30;25(1):79–86. doi: 10.1177/2472555219860771

Figure 4.

Figure 4.

Percent fold change of infection and cell viability. (A) Pentamidine and securinine were tested in a secondary stock threefold dose–response for their ability to prevent HPV infection compared with the positive control (PsV + cells) and negative control (cells only). (B) Pentamidine and securinine were tested in a secondary stock threefold dose–response for cell viability compared with the positive control (cell only).